More people entered the labor force, and not all were able to find jobs right away. Bad weather may have been a factor
Consumers like curation—stories that narrow the choices down to the best two or three
With yet another tweak to the health-care law, the Obama administration is heading off a popular Republican attack
Music executives are tapping services such as Shazam and Spotify to help predict tomorrow’s next big hits
In the five years since the most recent bottom, the stock market has very nearly tripled
Arunachalam Muruganantham, aka "Menstrual Man," designed simple devices that allow rural Indian women to make their own sanitary pads
The company's dubbing of storms with Greek and Latin names began in 2012 to help 'personalize' extreme weather
European MBA programs compete with top-tier U.S. schools for the best students at home and abroad
Organizations offer special training for senior entrepreneurs
By Pete Engardio
For nearly two decades, America's life sciences industry has benefited from a Chinese brain drain. Since 1985 some 10,000 mainlanders have earned biomedicine PhDs in the U.S.—and the vast majority stayed to work at U.S. pharmaceutical companies and research universities. Now some of China's brightest brains are returning home to start drug-research companies, run university programs, and establish operations for multinationals.
China's gain is not necessarily America's loss, however. Most of these "sea turtles," as the returnees are known, are building strategic tieups with U.S. drugmakers that could expand their pipelines of new drugs, speed up development time, reduce R&D costs—and gain inroads to China's rapidly growing drug market. Others are founding U.S. companies with China operations.
Following are some of the most influential sea turtles.